Methylprednisolone

Methylprednisolone is a synthetic glucocorticoid. Glucocorticoids penetrate cell membranes and bind to specific receptors in the cytoplasm. This conjugate then enters the cell nucleus and binds to DNA (chromosomes), initiating the transcription of mRNA and subsequently synthesizing various enzyme proteins. It is believed that systemically administered glucocorticoids ultimately exert multiple effects through these enzymes. The maximum pharmacological effect of corticosteroids occurs after the peak blood concentration, indicating that most of its effects are triggered by changes in enzyme activity rather than direct drug effects. Glucocorticoids not only have important effects on inflammatory and immune processes, but also affect carbohydrate, protein and fat metabolism, and have effects on the cardiovascular system, skeletal and muscular systems and the central nervous system. Acting on inflammatory and immune processes: Most of the therapeutic effects of glucocorticoids are related to their anti-inflammatory, immunosuppressive and anti-allergic properties, which lead to the following results: reduction of immunocompetent cells around inflammatory lesions; reduction of vasodilation; stabilization of lysosomal membranes; inhibition of phagocytosis; and reduction of the production of prostaglandins and related substances. The glucocorticoid-like effects (anti-inflammatory effects) of 4 mg of methylprednisolone are the same as those of 20 mg of hydrocortisone. Methylprednisolone has only a low mineralocorticoid-like effect (200 mg of methylprednisolone is equivalent to 1 mg of deoxycorticosterone). Effects on carbohydrate and protein metabolism: Glucocorticoids have the effect of breaking down proteins, and the released amino acids are converted into glucose and glycogen in the liver through the process of gluconeogenesis. Due to the reduced absorption of glucose by peripheral tissues, blood sugar levels and glucosuria are increased, which is particularly evident in patients with a tendency to diabetes. Effects on fat metabolism: Glucocorticoids have the effect of breaking down fat, which mainly affects the limbs. In addition, glucocorticoids have the effect of fat synthesis, which is particularly evident in the chest, neck and head. All of these lead to the redistribution of fat.

Sodium Succinate-6-Methylprednisolone

Systemic lupus erythematosus (and lupus nephritis); systemic dermatomyositis (polymyositis); acute rheumatic myocarditis; polymyalgia rheumatica; giant cell joints. Pemphigus; bullous dermatitis herpetiformis; exfoliative dermatitis; fungal disease; severe psoriasis; severe seborrheic dermatitis; seasonal or year-round allergic rhinitis; serum sickness; bronchial asthma; drug allergic reaction; contact dermatitis; atopic dermatitis; severe acute and chronic allergic and inflammatory diseases of the eye and its appendages, such as allergic corneal marginal ulcers; herpes zoster ophthalmicus; anterior ciliary infection, diffuse posterior chamber uveitis and choroiditis; sympathetic ophthalmia. Allergic conjunctivitis, keratitis, chorioretinitis; optic neuritis; iritis, iridocyclitis, pulmonary sarcoidosis; leukoderma that cannot be controlled by other methods

Adults · Conventional dose · Oral administration The initial dose is 4-48 mg once a day. The specific dosage can be determined according to the disease type and condition. Some patients may need a higher initial dose. Diseases that require higher doses clinically include multiple sclerosis (200 mg per day), organ transplantation (up to 7 mg/kg per day) and cerebral edema. The maintenance dose is 4-8 mg per day. · Intravenous administration 1. Auxiliary drugs for critical illness: methylprednisolone sodium succinate, the recommended dose is 15-30 mg/kg per day, intravenous injection for at least 30 minutes. According to clinical needs, it can be repeated every 4-6 hours within 48 hours. 2. Rheumatoid arthritis: 1g intravenous injection per day, for 1-4 consecutive days; or 1g per month, for 6 months. 3. Prevention of nausea and vomiting caused by tumor chemotherapy: (1) Mild to moderate vomiting, intravenous injection of methylprednisolone sodium succinate 250 mg (at least 5 minutes) 1 hour before chemotherapy. Chlorophenyltriazine can be given at the same time as the first dose to enhance the effect. (2) For severe vomiting, intravenous injection of methylprednisolone sodium succinate 250 mg once (injection for at least 5 minutes), administered 1 hour before chemotherapy, at the beginning of chemotherapy, and after chemotherapy. 4. Acute spinal cord injury: The initial dose is 30 mg/kg (intravenous injection for 15 minutes), and the drug should be started within 8 hours after the injury. After a large dose injection, pause for 45 minutes, followed by continuous intravenous drip of 5.4 mg/(kg·h) for 23 hours. 5. Immunosuppression: 800-1000 mg per day, added to 250-500 ml of 5% glucose injection, dripped over 4 hours, 3 days as a course of treatment. Can be repeated after 3-4 weeks. 6. Organ transplantation: 40-80 mg once, once or several times a day. 7. Rheumatic diseases: 1000 mg per day, for 1-4 consecutive days. Or 1000 mg per day, for 6 months. 8. Systemic lupus erythematosus: 1000 mg per day, for 3 consecutive days. 9. Pyelonephritis, nephritic lupus, etc.: 30 mg/kg once, once every other day, for 4 days. · Intra-articular injection once 10-40 mg. · Intramuscular injection once 10-40 mg. Children · Conventional dose · The dose can be reduced for intravenous administration, but the daily dose cannot be less than 0.5 mg/kg.

1. Cross-allergy: People who are allergic to other adrenal cortex hormones may also be allergic to this drug. 2. Contraindications: 1. Allergy to adrenal cortex hormones. 2. Systemic fungal infection. 3. Patients with the following diseases are generally not suitable for use: severe mental illness and history of severe mental illness, active peptic ulcer, recent gastrointestinal anastomosis, severe hypertension, obvious diabetes, uncontrolled infection (such as chickenpox, measles, tuberculosis and other fungal infections), severe osteoporosis. 3. Use with caution: 1. Heart disease or acute heart failure. 2. Diabetes. 3. Diverticulitis. 4. Emotionally unstable and with a tendency to mental illness. 5. Liver dysfunction. 6. Ocular herpes simplex. 7. Hyperlipoproteinemia. 8. Hypertension. 9. Hypothyroidism. 10. Myasthenia gravis. 11. Osteoporosis. 12. Gastritis, esophagitis, gastric ulcer and ulcerative colitis. 13. Renal impairment or stones. 14. Glaucoma. 4. For the effects of drugs on pregnancy, see Hydrocortisone. 5. For the effects of drugs on breastfeeding, see Hydrocortisone. 6. For the rest, see Hydrocortisone.

(1) Allergy to adrenal cortex hormone drugs. (2) Systemic fungal infection. (3) Patients with the following diseases are generally not suitable for use: severe mental illness or history of severe mental illness, active peptic ulcer, recent gastrointestinal anastomosis surgery, severe hypertension, obvious diabetes, uncontrolled infection (such as chickenpox, measles, tuberculosis and other fungal infections), severe osteoporosis.

Beneficial interactions: - Methylprednisolone can be used in combination with other antituberculosis chemotherapy to treat fulminant or disseminated pulmonary tuberculosis and combined meningitis with subarachnoid obstruction. - Methylprednisolone is often used in combination with alkylating agents, antimetabolites and vinca alkaloids for neoplastic diseases such as leukemia and lymphoma. Unfavorable interactions - The risk of gastrointestinal complications is increased when glucocorticoids are used in combination with ulcerogenic drugs (such as salicylates and N.S.A.I.). - The risk of impaired glucose tolerance is increased when glucocorticoids are used in combination with thiazide diuretics. - Glucocorticoids increase the need for insulin and oral hypoglycemic agents in patients with diabetes. - Patients taking corticosteroids should not receive vaccinia vaccination or other immunization measures, especially those taking high doses, because of the risk of neurological complications and/or lack of antibody response. - Corticosteroids should be used with caution in patients with hypoprothrombin when used in combination with acetylsalicylic acid.

Zhejiang Xianju Pharmaceutical Co., Ltd.

• Founded in:

  2000-06-26

• Address:

  No. 1, Xianyao Road, Xianju County, Taizhou City, Zhejiang Province

• Tax NO.:

  913300007047892221

• Registered Funds:

  989.204866 million yuan

• Website:

  Log in to view

• Email:

  Log in to view